BioCatalystWatch
EQWorkspace / EQ / OverviewCompany library
Price
Market cap
Next catalystQ2 2027; approximately six months after Phase 1 initiationEQ504 — Australian Phase 1 healthy-volunteer SAD/MAD study · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

EQ504

Small molecule

AhR

Upcoming / outlook

EQ504

Small molecule

AhR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EQ504

Small molecule

AhR

PreINDP1P2P3FilingApproved
Upcoming / outlook

EQ504

Small molecule

AhR

Upcoming / outlook

Other pipelines

EQ504

Small molecule

AhR

Peptide

IL-15 × IL-21

History / paused

CD6

PreINDP1P2P3FilingApproved

Peptide

IL-2 × IL-9 × IL-15

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

EQ PR & News

PR & News

EQ SEC archive